Lupin divests women's health specialty business in US to Evofem Biosciences for nearly $84 mn

Lupin announced the sale of its US commercial women’s health specialty business, focusing on Solosec, to Evofem Biosciences. Solosec, an FDA-approved single-dose treatment for bacterial vaginosis and trichomoniasis, is the key product involved. The deal includes potential payments up to USD 84 million based on future milestones.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d1Gyk7c
via IFTTT

0 comments:

Post a Comment